술폰아미드 시장 규모 : 투여 경로별, 용도별, 약물 유형별, 유통 채널별, 세계 예측(2024-2032년)

Global Sulphonamides Market will witness 4.8% CAGR between 2024 and 2032, driven by rising research and development activities. Sulphonamides, a class of antimicrobial agents known for their effectiveness against a broad spectrum of bacterial infections, are experiencing renewed interest due to advancements in medical research. This resurgence is fueled by the increasing prevalence of drug-resistant bacterial strains, which has heightened the need for novel and effective treatment options.

Researchers are exploring new sulphonamide derivatives and formulations to address these challenges and enhance efficacy. Innovations such as combination therapies and targeted delivery systems are being developed to improve treatment outcomes and minimize side effects. Additionally, ongoing studies are investigating the potential of sulphonamides in treating conditions beyond bacterial infections, including certain cancers and autoimmune disorders.

The rise in R&D investments by pharmaceutical companies and academic institutions is driving the discovery of new applications and improvements in sulphonamide treatments. As the healthcare sector continues to address emerging microbial threats and evolving medical needs, the demand for sulphonamides, supported by ongoing research and development, is anticipated to grow significantly.

The overall Sulphonamides Industry value is classified based on the route of administration, application, medication type, distribution channel, and region.

Based on the route of administration, the sulphonamides market revenue from the topical segment will register a commendable CAGR from 2024 to 2032. Topical sulphonamides are commonly used in ointments and creams to address infections such as acne, impetigo, and minor wounds. Their ability to provide targeted antimicrobial action with reduced systemic side effects makes them a preferred choice in dermatology. As the focus on accessible and efficient treatments for skin-related issues grows, the demand for topical sulphonamides is expected to rise. This trend reflects a broader interest in effective, localized treatments that offer convenience and precise therapeutic benefits.

In terms of application, the gastrointestinal (GIT) infection segment will witness appreciable growth from 2024 to 2032. Sulphonamides are valuable in managing bacterial infections in the gastrointestinal tract, such as those caused by Salmonella and Shigella. Their targeted action helps in alleviating symptoms and preventing complications associated with GIT infections. As cases of gastrointestinal infections become more prevalent and antibiotic resistance grows, the need for effective treatments like sulphonamides increases. Their role in addressing both acute and chronic GIT conditions contributes to the growing market demand, reflecting their continued importance in managing digestive health and infection control.

Europe sulphonamides market will exhibit a notable CAGR from 2024 to 2032. European healthcare systems rely on sulphonamides for their effectiveness against various pathogens, including those resistant to other antibiotics. The rise in chronic diseases and infections, coupled with the need for effective antimicrobial agents, is driving demand. Additionally, European regulatory support and investment in pharmaceutical research are facilitating the development of new sulphonamide formulations. As awareness of antibiotic resistance grows and healthcare needs evolve, the demand for sulphonamides in Europe is expected to continue increasing, reflecting their crucial role in modern medicine.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of bacterial infection worldwide
    • 3.2.1.2 Growing R&D activities in pharmaceutical companies
    • 3.2.1.3 Growing demand for combination antibiotic therapies
    • 3.2.1.4 Supportive government initiatives
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects associated with the use of sulfa drugs
    • 3.2.2.2 Availability of alternative antibiotics
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porters analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Oral
• 5.3 Topical
• 5.4 Other routes of administration

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Skin infection
• 6.3 Gastrointestinal (GIT) infection
• 6.4 Urinary tract infection (UTI)
• 6.5 Respiratory tract infection (RTI)
• 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By Medication Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Branded
• 7.3 Generics

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Allergan
• 10.2 Amneal Pharmaceuticals LLC
• 10.3 Aurobindo Pharma
• 10.4 Bausch & Lomb Incorporated
• 10.5 Cadila Pharmaceuticals Ltd.
• 10.6 Cipla Ltd.
• 10.7 Dr. Reddy's Laboratories
• 10.8 F. Hoffmann-La Roche Ltd.
• 10.9 GSK plc
• 10.10 Glenmark Pharma Ltd.
• 10.11 Lexine Technochem Pvt. Ltd.
• 10.12 Monarch Pharmaceuticals
• 10.13 Pfizer Inc.
• 10.14 Sun Pharmaceutical Industries Ltd.
• 10.15 Teva Pharmaceutical Industries Ltd.